ONCY logo

ONCY
Oncolytics Biotech, Inc.

7,545
Mkt Cap
$121.93M
Volume
466,548.00
52W High
$1.51
52W Low
$0.3258
PE Ratio
-4.66
ONCY Fundamentals
Price
$1.05
Prev Close
$1.05
Open
$1.03
50D MA
$0.9678
Beta
0.92
Avg. Volume
844,665.43
EPS (Annual)
-$0.30
P/B
-29.86
Rev/Employee
$0.00
$79.14
Loading...
Loading...
News
all
press releases
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.03) per share f...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Equities Analysts Issue Forecasts for ONCY Q1 Earnings
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Oncolytics Biotech in a report released on Friday, April 10th. HC...
MarketBeat·1d ago
News Placeholder
Q1 Earnings Estimate for ONCY Issued By Zacks Research
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th...
MarketBeat·5d ago
News Placeholder
What is Zacks Research's Forecast for ONCY FY2026 Earnings?
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at Zacks Research issued their FY2026 earnings per share estimates for Oncolytics Biotech in a research note issued to...
MarketBeat·6d ago
News Placeholder
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two...
MarketBeat·8d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·10d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Releases Earnings Results, Misses Expectations By $0.02 EPS
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by...
MarketBeat·13d ago
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·26d ago
News Placeholder
James Parsons Acquires 10,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director James Parsons acquired 10,000 shares of the firm's stock in a transaction dated Wednesday, March 11th. The stock was bought at an...
MarketBeat·1mo ago
News Placeholder
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director James Parsons acquired 10,000 shares of Oncolytics Biotech stock in a transaction that occurred on Wednesday, March 11th. The stock...
MarketBeat·1mo ago
<
1
2
...
>

Latest ONCY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.